157023-34-2

Basic information

• Product Name: 1-Cbz-4-Aminomethylpiperidine
• Synonyms: BENZYL 4-(AMINOMETHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;BUTTPARK 93\50-51;4-(AMINOMETHYL)PIPERIDINE, N-CBZ PROTECTED;4-AMINOMETHYL-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;4-AMINOMETHYL-1-N-CBZ-PIPERIDINE;1-CBZ-4-AMINOMETHYLPIPERIDINE;N-CBZ-4-AMINOMETHYLPIPERIDINE;4-(AMINOMETHYL)TETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• CAS NO: 157023-34-2
• Molecular Formula: C₁₄H₂₀N₂O₂
• Molecular Weight: 248.32
• Mol File: 157023-34-2.mol

Chemical Properties

• Boiling Point: 385.709 °C at 760 mmHg
• Flash Point: 187.07 °C
• Appearance: /
• Density: 1.126 g/cm³
• PKA: 10.13±0.29(Predicted)
• CAS DataBase Reference: 1-Cbz-4-Aminomethylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Cbz-4-Aminomethylpiperidine(157023-34-2)
• EPA Substance Registry System: 1-Cbz-4-Aminomethylpiperidine(157023-34-2)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 157023-34-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Cbz-4-Aminomethylpiperidine is used as a key intermediate for the synthesis of a variety of bioactive molecules, including antipsychotics, analgesics, and antihistamines. Its carboxybenzyl protecting group facilitates the controlled deprotection of the amine function, enabling the attachment of different functional groups to the piperidine core, which is crucial for the development of new drugs with improved pharmacological properties.
Used in Organic Synthesis:
1-Cbz-4-Aminomethylpiperidine is used as a building block in organic synthesis for the preparation of complex organic molecules. Its protected amine group allows for selective reactions at other sites on the molecule, providing a strategic advantage in the synthesis of target compounds with specific biological activities.
Used in Medicinal Chemistry Research:
1-Cbz-4-Aminomethylpiperidine is used as a starting material in medicinal chemistry research to explore the structure-activity relationships of piperidine-containing compounds. By modifying the substituents on the piperidine ring and the attached functional groups, researchers can investigate the impact of these changes on the biological activity and pharmacokinetic properties of the resulting compounds.

Upstream product

• 153747-01-4 4-(phthalimidomethyl)piperidine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 7144-05-0 4-Aminomethylpiperidine 
• 31139-36-3 dibenzyl dicarbonate 
• 501-53-1 benzyl chloroformate 
• 71207-29-9 N-hexahydro-4-pyridinylmethyl-N-phenylmethylidenamine 
• 396072-76-7 N-(1-benzyloxycarbonylpiperidin-4-ylmethyl)phthalimide 

Downstream Products

• 366022-97-1 4-[(4-cyano-benzoylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 
• 366022-98-2 4-[(4-cyano-benzenesulfonylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 
• 396072-77-8 4-{[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butylamino]-methyl}-piperidine-1-carboxylic acid benzyl ester 
• 856886-35-6 C₂₂H₃₁N₃O₃S 
• 172348-56-0 benzyl 4-(((tert-butoxycarbonyl)amino)methyl)piperidine-1-carboxylate 
• 471254-24-7 benzyl 4-[({[2-(methylsulfonyl)pyrimidin-4-yl]carbonyl}amino)methyl]piperidine-1-carboxylate 
• 1417453-04-3 benzyl 4-{[({2-[(tert-butoxycarbonyl)amino]-1,3-thiazol-5-yl}carbonyl)amino]methyl}piperidine-1-carboxylate 
• 455265-89-1 4-[(5-fluoro-pyrimidin-2-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 
• 455265-38-0 benzyl 4-{[(6-chloro-3-pyridazinyl)amino]methyl}-1-piperidinecarboxylate 
• 455265-73-3 4-[(2-chloro-6-methyl-pyrimidin-4-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 
• 455265-96-0 4-(Pteridin-4-ylaminomethyl)-piperidine-1-carboxylic acid benzyl ester 
• 455266-45-2 4-[(3-fluoro-pyridin-2-ylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Discovery of diaminobutane derivatives as Ca(2+)-permeable AMPA receptor antagonists.

We designed and synthesized a series of the polyamine derivatives as potent Ca(2+)-permeable AMPA receptor antagonists. In the course of this study, we found that the polyamine derivatives exhibited strong hypotensive activity which was undesirable activity for neuroprotective agents. Therefore, we tried to find non-hypotensive antagonists by structural modification of such compounds. Through this derivatization, we obtained the diamine compounds having desired profiles. Especially, compound 8f, which was non-hypotensive and potent Ca(2+)-permeable AMPA receptor antagonist, showed neuroprotective effects in transient global ischemia models in gerbils.

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

Compounds represented by Formula (I): 1or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-γ(a) PRODUCTION INHIBITOR

N-Substituted-N'-substituted urea derivatives represented by the following formula, analogs thereof or pharmaceutically acceptable salts thereof are herein provided. These compounds show a TNF- α production inhibitory activity.

Synthesis of polyamine derivatives having non-hypotensive Ca2+-permeable AMPA receptor antagonist activity

In order to obtain non-hypotensive and Ca2+-permeable AMPA receptor antagonists, we have synthesized a series of 1,4-bis(4-piperidinylmethyl)diaminobutanes. Compounds 13b, c, f had desirable properties.

Dibasic inhibitors of human mast cell tryptase. Part 3: Identification of a series of potent and selective inhibitors containing the benzamidine functionality

A survey of charged groups and linkers for a series of symmetrical and unsymmetrical dibasic inhibitors is described, leading to several classes of potent and selective inhibitors. In particular, the benzamidine functionality was identified as the most potent charged group investigated.

SRC kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

Fibrinogen receptor antagonists

Novel fibrinogen receptor antagonists of the formula: are provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.